FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Among patients with metastatic pancreatic cancer, combination chemotherapy with fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) leads to longer overall survival than gemcitabine therapy. We compared the efficacy and safety of a modified FOLFIRINOX regimen with gemcitabine as adjuvant therapy in patients with resected pancreatic cancer. METHODS: We randomly assigned 493 patients with resected pancreatic ductal adenocarcinoma to receive a modified FOLFIRINOX regimen (oxaliplatin [85 mg per square meter of body-surface area], irinotecan [180 mg per square meter, reduced to 150 mg per square meter after a protocol-specified safety analysis], leucovorin [400 mg per square meter], and fluorouracil [2400 mg per square meter] every 2 weeks) or gemcitabine (1000 mg per square meter on days 1, 8, and 15 every 4 weeks) for 24 weeks. The primary end point was disease-free survival. Secondary end points included overall survival and safety. RESULTS: At a median follow-up of 33.6 months, the median disease-free survival was 21.6 months in the modified-FOLFIRINOX group and 12.8 months in the gemcitabine group (stratified hazard ratio for cancer-related event, second cancer, or death, 0.58; 95% confidence interval [CI], 0.46 to 0.73; P<0.001). The disease-free survival rate at 3 years was 39.7% in the modified-FOLFIRINOX group and 21.4% in the gemcitabine group. The median overall survival was 54.4 months in the modified-FOLFIRINOX group and 35.0 months in the gemcitabine group (stratified hazard ratio for death, 0.64; 95% CI, 0.48 to 0.86; P=0.003). The overall survival rate at 3 years was 63.4% in the modified-FOLFIRINOX group and 48.6% in the gemcitabine group. Adverse events of grade 3 or 4 occurred in 75.9% of the patients in the modified-FOLFIRINOX group and in 52.9% of those in the gemcitabine group. One patient in the gemcitabine group died from toxic effects (interstitial pneumonitis). CONCLUSIONS: Adjuvant therapy with a modified FOLFIRINOX regimen led to significantly longer survival than gemcitabine among patients with resected pancreatic cancer, at the expense of a higher incidence of toxic effects. (Funded by R&D Unicancer and others; ClinicalTrials.gov number, NCT01526135 ; EudraCT number, 2011-002026-52 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Polychemotherapy, either with 5-fluorouracil (5-FU), irinotecan and oxaliplatin in combination with folinic acid (FOLFIRINOX), or with gemcitabine and nab-paclitaxel (GnP), is considered the standard of care for patients suffering from metastatic PDAC (mPDAC)3,4.”
From Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer (2023) · cites this paper as [4]
In the citing paper
“Less than half of all patients respond to the primary treatment for PDAC, chemotherapy3,4”
From Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer (2023) · cites this paper as [4]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Siegel, R. L., Miller, K. D., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21442 · Cited by 16,579
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011923 · Cited by 7,810
Self-citationRahib, L., Smith, B. D., Aizenberg, R., Rosenzweig, A. B., Fleshman, J. M., & Matrisian, L. M. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0155 · Cited by 7,094
TNM Classification of Malignant Tumors
Carter, D. (1998) · The American Journal of Surgical Pathology · doi:10.1097/00000478-199810000-00016 · Cited by 6,330
Proportional hazards tests and diagnostics based on weighted residuals
GRAMBSCH, P. M., & THERNEAU, T. M. (1994) · Biometrika · doi:10.1093/biomet/81.3.515 · Cited by 5,885
A Randomized Trial of Chemoradiotherapy and Chemotherapy after Resection of Pancreatic Cancer
Neoptolemos, J. P., Stocken, D. D., Friess, H., Bassi, C., Dunn, J. A., Hickey, H., Beger, H., Fernandez-Cruz, L., Dervenis, C., Lacaine, F., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032295 · Cited by 2,716
Oettle, H., Post, S., Neuhaus, P., Gellert, K., Langrehr, J., Ridwelski, K., Schramm, H., Fahlke, J., Zuelke, C., Burkart, C., et al. (2007) · JAMA · doi:10.1001/jama.297.3.267 · Cited by 2,419
Neoptolemos, J. P., Palmer, D. H., Ghaneh, P., Psarelli, E. E., Valle, J. W., Halloran, C. M., Faluyi, O., O'Reilly, D. A., Cunningham, D., Wadsley, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32409-6 · Cited by 1,926
Self-citationOettle, H., Neuhaus, P., Hochhaus, A., Hartmann, J. T., Gellert, K., Ridwelski, K., Niedergethmann, M., Zülke, C., Fahlke, J., Arning, M. B., et al. (2013) · JAMA · doi:10.1001/jama.2013.279201 · Cited by 1,794
Research works printed but not linked: 1
- Early Breast Cancer Trialists’ Collaborative Group. Treatment of early breast cancer. Vol. 1. Worldwide evidence 1985–1990. Oxford England: Oxford University Press 1990.
Cited by
Items 201–300 of 1,002
van Dam, J. L., Verkolf, E. M. M., Dekker, E. N., Bonsing, B. A., Bratlie, S. O., Brosens, L. A. A., Busch, O. R., van Driel, L. M. J. W., van Eijck, C. H. J., Feshtali, S., et al. (2023) · BMC Cancer · doi:10.1186/s12885-023-11141-5 · Cited by 76
“In 2018, the French-Cana - dian PRODIGE 24/CCTG PA.6 randomized controlled trial (RCT) showed the superiority of adjuvant mFOL-FIRINOX (5-fluorouracil with leucovorin, irinotecan, and oxaliplatin) over adjuvant gemcitabine [5].”
BackgroundMethodInfluentialJanssen, Q. P., van Dam, J. L., van Bekkum, M. L., Bonsing, B. A., Bos, H., Bosscha, K. P., Bouwense, S. A. W., Brouwer-Hol, L., Bruynzeel, A. M. E., Busch, O. R., et al. (2025) · The Lancet Oncology · doi:10.1016/s1470-2045(25)00363-8 · Cited by 95
Microdissected pancreatic cancer proteomes reveal tumor heterogeneity and therapeutic targets
Large, T. Y. S. L., Mantini, G., Meijer, L. L., Pham, T. V., Funel, N., van Grieken, N. C. T., Kok, B., Knol, J. C., van Laarhoven, H. W. M., Piersma, S. R., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.138290 · Cited by 66
“New chemotherapeutic regimens have improved the survival rate by several months (11, 12), and, hopefully, (neo)adjuvant multimodal approaches will improve survival further (13, 14).”
BackgroundPeng, H., James, C. A., Cullinan, D. R., Hogg, G. D., Mudd, J. L., Zuo, C., Takchi, R., Caldwell, K. E., Liu, J., DeNardo, D. G., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0998 · Cited by 61
Neoadjuvant Therapy for Resectable Pancreatic Cancer: An Evolving Paradigm Shift
Chawla, A., & Ferrone, C. R. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01085 · Cited by 60
Proposal for a definition of "Oligometastatic disease in pancreatic cancer"
Damanakis, A. I., Ostertag, L., Waldschmidt, D., Kütting, F., Quaas, A., Plum, P. S., Bruns, C. J., Gebauer, F., & Popp, F. (2019) · BMC Cancer · doi:10.1186/s12885-019-6448-9 · Cited by 60
Adjuvant and neoadjuvant treatment for pancreatic adenocarcinoma
Motoi, F., & Unno, M. (2020) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyaa018 · Cited by 58
Cai, B., Lu, Z., Neoptolemos, J. P., Diener, M. K., Li, M., Yin, L., Gao, Y., Wei, J., Chen, J., Guo, F., et al. (2021) · Langenbeck s Archives of Surgery · doi:10.1007/s00423-021-02080-5 · Cited by 60
A comprehensive review of the multifaceted role of the microbiota in human pancreatic carcinoma
Pandya, G., Kirtonia, A., Singh, A. P., Goel, A., Mohan, C. D., Rangappa, K. S., Pandey, A. K., Kapoor, S., Tandon, S., Sethi, G., et al. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.05.027 · Cited by 62
Farshadi, E. A., Chang, J., Sampadi, B., Doukas, M., Van 't Land, F., van der Sijde, F., Vietsch, E. E., Pothof, J., Koerkamp, B. G., & van Eijck, C. H. J. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1681 · Cited by 60
Davis, N. E., Hue, J., Kyasaram, R., Elshami, M., Graor, H. J., Zarei, M., Ji, K., Katayama, E. S., Hajihassani, O., Loftus, A., et al. (2022) · Psycho-Oncology · doi:10.1002/pon.5945 · Cited by 48
Schiff, J. P., Price, A. T., Stowe, H. B., Laugeman, E., Chin, R.-I., Hatscher, C., Pryser, E., Cai, B., Hugo, G. D., Kim, H. J., et al. (2022) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2022.08.026 · Cited by 60
Chikhladze, S., Lederer, A., Kousoulas, L., Reinmuth, M., Sick, O., Fichtner‐Feigl, S., & Wittel, U. A. (2019) · World Journal of Surgical Oncology · doi:10.1186/s12957-019-1732-3 · Cited by 60
Sunami, Y., Häußler, J., & Kleeff, J. H. (2020) · Cancers · doi:10.3390/cancers12123770 · Cited by 69
Ma, H., Chen, X., Mo, S., Zhang, Y., Mao, X., Chen, J., Liu, Y., Tong, W., Lu, Z., Yu, S., et al. (2023) · Cell Death and Differentiation · doi:10.1038/s41418-023-01188-z · Cited by 67
“Gemcitabine (GEM) is a first-line chemotherapy regimen for pancreatic cancer but its clinical effect is limited owing to chemoresistance [30, 31].”
BackgroundCirculating microRNAs as Potential Biomarkers in Pancreatic Cancer—Advances and Challenges
Seyhan, A. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241713340 · Cited by 69
“8 months) as compared to gemcitabine monotherapy [7,9].”
BackgroundOvercoming therapy resistance in pancreatic cancer: New insights and future directions
Espona‐Fiedler, M., Patthey, C., Lindblad, S., Sarró, I., & Öhlund, D. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116492 · Cited by 71
“…classification into 3 subgroups: (i) local disease, when no vascular involvement is found in the tumor; (ii) regional disease, when the tumor with varying degrees of vascular involvement is defined either as borderline resectable or locally advanced disease; and (iii) metastatic disease [21 – 25].”
A comprehensive analysis of clinical trials in pancreatic cancer: what is coming down the pike?
Katayama, E., Hue, J. J., Bajor, D. L., Ocuin, L. M., Ammori, J. B., Hardacre, J. M., & Winter, J. M. (2020) · Oncotarget · doi:10.18632/oncotarget.27727 · Cited by 62
Kamarajah, S. K., Sonnenday, C. J., Cho, C. S., Frankel, T. L., Bednar, F., Lawrence, T. S., & Nathan, H. (2019) · Annals of Surgery · doi:10.1097/sla.0000000000003242 · Cited by 58
Michl, P., Löhr, M. J., Neoptolemos, J. P., Capurso, G., Rebours, V., Malats, N., Ollivier, M., & Ricciardiello, L. (2021) · United European Gastroenterology Journal · doi:10.1002/ueg2.12123 · Cited by 62
“The impact of this strategy on the survival of PDAC is significant, but still 60%–70% of patients relapse at 3 years.(12) Unfortunately, new personalized treatment strategies, through improved multimodal approaches”
BackgroundMiddleton, G., Robbins, H. L., André, F., & Swanton, C. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.11.004 · Cited by 61
Janssen, Q. P., van Dam, J. L., Doppenberg, D., Prakash, L. R., van Eijck, C. H. J., Jarnagin, W. R., O'Reilly, E. M., Paniccia, A., Besselink, M. G., Katz, M. H. G., et al. (2022) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djac018 · Cited by 58
“The multidrug combination regimen of 5-fluorouracil with leucovorin, irinotecan, and oxaliplatin ([m]FOLFIRINOX) has been shown in 2 randomized controlled trials (RCTs) to be superior to gemcitabine in the metastatic and adjuvant settings (3,4).”
Self-citationProspective observational study on biomarkers of response in pancreatic ductal adenocarcinoma
Jiang, L., Qin, J., Dai, Y., Zhao, S., Zhan, Q., Cui, P., Ren, L., Wang, X., Zhang, R., Gao, C., et al. (2024) · Nature Medicine · doi:10.1038/s41591-023-02790-x · Cited by 65
“However, even with intensive adjuvant chemotherapy, recurrence rates remain extremely high, reaching 69–75% within 2 years 5 .”
Self-citationCurrent Strategies and Future Perspectives for Precision Medicine in Pancreatic Cancer
Regel, I., Mayerle, J. V., & Mukund, M. U. (2020) · Cancers · doi:10.3390/cancers12041024 · Cited by 68
Myeloid Cell Mediated Immune Suppression in Pancreatic Cancer
Kemp, S. B., Pasca di Magliano, M., & Crawford, H. C. (2021) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2021.07.006 · Cited by 55
Zhang, J., Song, J., Tang, S., Zhao, Y., Wang, L., Luo, Y., Tang, J., Ji, Y., Wang, X., Li, T., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112620 · Cited by 71
Roles of microbiota in pancreatic cancer development and treatment
Cruz, M. S., Tintelnot, J., & Gagliani, N. (2024) · Gut Microbes · doi:10.1080/19490976.2024.2320280 · Cited by 68
Pancreatic surgery outcomes: multicentre prospective snapshot study in 67 countries
Collaborative, P. O., Fusai, G., Raptis, D. A., Hilal, M. A., Bassi, C., Besselink, M. G., Conlon, K. C., Davidson, B. R., Chiaro, M. D., Dervenis, C., et al. (2023) · British journal of surgery · doi:10.1093/bjs/znad330 · Cited by 57
Self-citationSivakumar, S., Abu‐Shah, E., Ahern, D., Arbe-Barnes, E. H., Jainarayanan, A., Mangal, N., Reddy, S., Rendek, A., Easton, A., Kurz, E., et al. (2021) · Cancers · doi:10.3390/cancers13081776 · Cited by 48
“Early diagnosis with surgical resection followed by combination chemotherapy offers the best chance of long-term survival [3].”
BackgroundFu, X., Zhang, X., Huang, D., Mao, L., Qiu, Y., & Zhao, Y. (2021) · Chemical Engineering Journal · doi:10.1016/j.cej.2021.133362 · Cited by 57
Seelen, L. W. F., van Oosten, A. F., Brada, L. J. H., Groot, V. P., Daamen, L. A., Walma, M. S., van der Lek, B. F., Liem, M. S. L., Patijn, G. A., Stommel, M. W. J., et al. (2022) · Annals of Surgery · doi:10.1097/sla.0000000000005666 · Cited by 63
Neoadjuvant treatment for resectable pancreatic adenocarcinoma: What is the best protocol?
Motoi, F., & Unno, M. (2020) · Annals of Gastroenterological Surgery · doi:10.1002/ags3.12311 · Cited by 56
NF-κB and Pancreatic Cancer; Chapter and Verse
Silke, J., & O’Reilly, L. A. (2021) · Cancers · doi:10.3390/cancers13184510 · Cited by 57
“Multiple aspects of NF-κB pathway signaling outcomes impact on acquired resistance against gemcitabine, platinum agents and topoisomerase inhibitors, part of the FOLFIRINOX regime [31,194,195].”
BackgroundXiao, W., Pahlavanneshan, M., Eun, C.-Y., Zhang, X., DeKalb, C., Mahgoub, B., Knaneh-Monem, H., Shah, S., Sohrabi, A., Seidlits, S. K., et al. (2022) · Matrix Biology Plus · doi:10.1016/j.mbplus.2022.100111 · Cited by 65
“For the majority of patients diagnosed with advanced PDAC, chemotherapy such as gemcitabine is considered the standard of care [5].”
BackgroundZoetemelk, M., Ramzy, G. M., Rausch, M., & Nowak-Sliwinska, P. M. (2020) · Molecules · doi:10.3390/molecules25112614 · Cited by 63
Clinical Trials of Systemic Chemotherapy for Resectable Pancreatic Cancer: A Review
Mavros, M. N., Moris, D., Karanicolas, P. J., Katz, M. H. G., O'Reilly, E. M., & Pawlik, T. M. (2021) · JAMA Surgery · doi:10.1001/jamasurg.2021.0149 · Cited by 58
Riedl, J. M., Posch, F., Horvath, L., Gantschnigg, A., Renneberg, F., Schwarzenbacher, E., Moik, F., Barth, D. A., Rossmann, C. H., Stotz, M., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.03.040 · Cited by 61
Carbon ion radiotherapy in pancreatic cancer: A review of clinical data
Liermann, J., Shinoto, M., Syed, M., Debus, J., Herfarth, K. K., & Naumann, P. (2020) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2020.05.012 · Cited by 58
Cancer immunotherapy via synergistic coactivation of myeloid receptors CD40 and Dectin-1
Wattenberg, M. M., Coho, H., Herrera, V. M., Graham, K. L., Stone, M. L., Xue, Y., Chang, R. B., Cassella, C. R., Liu, M., Choi-Bose, S., et al. (2023) · Science Immunology · doi:10.1126/sciimmunol.adj5097 · Cited by 57
Postoperative surveillance of pancreatic cancer patients
Daamen, L. A., Groot, V. P., Intven, M., Besselink, M. G., Busch, O. R., Koerkamp, B. G., Mohammad, N. H., Hermans, J. J., van Laarhoven, H. W. M., Nuyttens, J. J. M. E., et al. (2019) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2019.05.031 · Cited by 55
Non-coding RNA biomarkers in pancreatic ductal adenocarcinoma
Sharma, G. G., Okada, Y., Hoff, D. D. V., & Goel, A. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.10.001 · Cited by 61
Belfiori, G., Crippa, S., Aleotti, F., Pagnanelli, M., Tamburrino, D., Gasparini, G., Partelli, S., Andreasi, V., Rubini, C., Zamboni, G., et al. (2021) · Annals of Surgical Oncology · doi:10.1245/s10434-021-10401-7 · Cited by 54
Pietrasz, D., Renault, S., Taïeb, J., Dahan, L., Postel, M., Durand-Labrunie, J., Malicot, K. L., Mulot, C., Rinaldi, Y., Phelip, J., et al. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01624-2 · Cited by 63
Self-citationClinical immunotherapy in pancreatic cancer
Ye, X., Yu, Y., Zheng, X., & Ma, H. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03632-6 · Cited by 62
You, M. S., Lee, S. H., Choi, Y. H., Shin, B., Paik, W. H., Ryu, J. K., Kim, Y., Jang, D. K., Lee, J. K., Kwon, W., et al. (2019) · BMC Cancer · doi:10.1186/s12885-019-6193-0 · Cited by 52
Alewine, C., Ahmad, M. I., Peer, C. J., Hu, Z. I., Lee, M.-J., Yuno, A., Kindrick, J. D., Thomas, A., Steinberg, S. M., Trepel, J. B., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2586 · Cited by 52
Inhibitors of the Cancer Target Ribonucleotide Reductase, Past and Present
Huff, S. E., Winter, J. M., & Dealwis, C. G. (2022) · Biomolecules · doi:10.3390/biom12060815 · Cited by 70
Desmoplastic stromal signatures predict patient outcomes in pancreatic ductal adenocarcinoma
Mascharak, S., Guo, J. L., Foster, D. S., Khan, A., Davitt, M. F., Nguyen, A. T., Burcham, A. R., Chinta, M. S., Guardino, N. J., Griffin, M., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101248 · Cited by 66
Ikezawa, K., Urabe, M., Kai, Y., Takada, R., Akita, H., Nagata, S., & Ohkawa, K. (2023) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyad176 · Cited by 58
Local radicality and survival outcome of pancreatic cancer surgery
Niesen, W., Hank, T. P., Büchler, M. W., & Strobel, O. (2019) · Annals of Gastroenterological Surgery · doi:10.1002/ags3.12273 · Cited by 58
Miller, C., Barkun, A., Martel, M., & Chen, Y.-I. (2019) · Endoscopy International Open · doi:10.1055/a-0998-8129 · Cited by 48
Покатаев, И. А., Fedyanin, M. Y., Максимовна, П. Е., As, P., Agafonova, J. A., Menshikova, S. F., Tryakin, A. A., Rumyantsev, А. А., & Tjulandin, S. (2020) · ESMO Open · doi:10.1136/esmoopen-2019-000578 · Cited by 54
Design principles of drug combinations for chemotherapy
Wu, D., Pusuluri, A., Vogus, D. R., Krishnan, V., Shields, C. W., Kim, J., Razmi, A. N., & Mitragotri, S. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.04.018 · Cited by 54
Total Neoadjuvant Therapy for Operable Pancreatic Cancer
Kim, R. Y., Christians, K. K., Aldakkak, M., Clarke, C. N., George, B., Kamgar, M., Khan, A. H., Kulkarni, N. M., Hall, W. A., Erickson, B. A., et al. (2020) · Annals of Surgical Oncology · doi:10.1245/s10434-020-09149-3 · Cited by 54
“Lymph nodes examined 26 [20, 33] 29 [22, 36] 25 [20, 32] 0.”
A Glimmer of Hope for Pancreatic Cancer
Kindler, H. L. (2018) · New England Journal of Medicine · doi:10.1056/nejme1813684 · Cited by 52
The TRIANGLE operation for pancreatic head and body cancers: early postoperative outcomes
Klotz, R., Hackert, T., Heger, P., Probst, P., Hinz, U., Loos, M., Berchtold, C., Mehrabi, A., Schneider, M. A., Müller-Stich, B. P., et al. (2021) · HPB · doi:10.1016/j.hpb.2021.06.432 · Cited by 61
Cabasag, C. J., Arnold, M., Rutherford, M. J., Bardot, A., Ferlay, J., Morgan, E., Little, A. L., De, P., Dixon, E., Woods, R. R., et al. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-01752-3 · Cited by 60
“For instance, in the last decade, FOLFIRINOX therapy (a combination of oxaliplatin, irinotecan, fluorouracil, and leucovorin) has increasingly been recommended as first-line chemotherapy for metastatic pancreatic cancer [23, 24], although it continues to be arguable whether the preferred first-line regimen is FOLFIRIN…”
BackgroundSchepis, T., Lucia, S. S. D., Pellegrino, A., GAUDIO, A. D., Maresca, R., Coppola, G., Chiappetta, M. F., Gasbarrini, A., Franceschi, F., Candelli, M., et al. (2023) · Cancers · doi:10.3390/cancers15133423 · Cited by 59
“in the PRODIGE-24 trial, although it is mainly used in patients with good performance status [109].”
MethodDendritic Cell–Based Immunotherapy in Patients With Resected Pancreatic Cancer
Land, F. R. V. ‘., Willemsen, M., Bezemer, K., van der Burg, S. H., van den Bosch, T. P. P., Doukas, M., Fellah, A., Kolijn, P. M., Langerak, A. W., Moskie, M., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.02585 · Cited by 64
“1,25 Most patients developed fever (n 5 28, 68”
BackgroundImmunotherapy of pancreatic cancer
Sunami, Y., & Kleeff, J. H. (2019) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2019.03.006 · Cited by 57
Environmental Risk Factors of Pancreatic Cancer
Tsai, H., & Chang, J. S.-M. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8091427 · Cited by 64
Lundgren, S., Elebro, J., Heby, M., Nodin, B., Leandersson, K., Micke, P., Jirström, K., & Mezheyeuski, A. (2020) · International Journal of Cancer · doi:10.1002/ijc.32945 · Cited by 57
Inoue, Y., Saiura, A., Oba, A., Ono, Y., Mise, Y., Ito, H., Sasaki, T., Ozaka, M., Sasahira, N., & Takahashi, Y. (2020) · Journal of Hepato-Biliary-Pancreatic Sciences · doi:10.1002/jhbp.844 · Cited by 51
“Agents FOLFIRINOX/GNP 21 (68%) 7 (11%) Gemcitabine/S1 2 (6%) 31 (51%) Others 1 (3%) 2 (3%) Best supportive care 7 (23%) 21 (34%) Duration of chemotherapy (mo)a 6 (1-14) 4 (1-27) .”
Molecular Subtyping and Precision Medicine for Pancreatic Cancer
Froeling, F. E. M., Casolino, R., Pea, A., Biankin, A. V., Chang, D. K.-F., & Precision-Panc, O. B. O. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10010149 · Cited by 54
“8 months with gemcitabine [11] and has become the standard of care for fit patients with resectable disease.”
BackgroundDrug-loaded PCL electrospun nanofibers as anti-pancreatic cancer drug delivery systems
Mitxelena‐Iribarren, O., Riera-Pons, M., Pereira, S., Calero-Castro, F. J., Tuñón, J. M. C., Ruiz, F. J. P., Mujika, M., & Arana, S. (2022) · Polymer Bulletin · doi:10.1007/s00289-022-04425-6 · Cited by 56
Zheng, S., Tian, Q., Yuan, Y., Sun, S., Li, T., Xia, R., He, R., Luo, Y., Lin, Q., Fu, Z., et al. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02854-3 · Cited by 56
He, C., Wang, J., Sun, S., Zhang, Y., & Li, S. (2019) · Journal of Oncology · doi:10.1155/2019/9346017 · Cited by 50
Lee, Y. S., Lee, J.-C., Yang, S. Y., Kim, J., & Hwang, J. (2019) · Scientific Reports · doi:10.1038/s41598-019-52167-9 · Cited by 57
Markov, S. D., Perales-Patón, J., Bockorny, B., Dopazo, A., Muñoz, M., Baños, N., Bonilla, V., Menéndez, C., Durán, Y., Huang, L., et al. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-1166 · Cited by 57
Sunami, Y., Boeker, V., & Kleeff, J. H. (2021) · Cancers · doi:10.3390/cancers13040697 · Cited by 59
Slimano, F., Baudouin, A., Zerbit, J., Deldicque, A., Thomas‐Schoemann, A., Chevrier, R., Daouphars, M., Madelaine, I., Pourroy, B., Tournamille, J., et al. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102063 · Cited by 53
Mungo, B., Croce, C., Oba, A., Ahrendt, S. A., Gleisner, A., Friedman, C., Schulick, R. D., & Chiaro, M. D. (2020) · Annals of Surgical Oncology · doi:10.1245/s10434-020-08916-6 · Cited by 52
Kinny‐Köster, B., van Oosten, F., Habib, J. R., Javed, A. A., Cameron, J. L., Lafaro, K. J., Burkhart, R. A., Burns, W. R., He, J. P., Fishman, E. K., et al. (2020) · Surgery · doi:10.1016/j.surg.2020.07.054 · Cited by 49
Mercanti, L., Sindaco, M., Mazzone, M., Marcantonio, M. C. D., Piscione, M., Muraro, R., & Mincione, G. (2023) · Cancers · doi:10.3390/cancers15112923 · Cited by 62
“By contrast, the combination of nab-paclitaxel plus gemcitabine or FOLFIRINOX has a little impact on overall survival [59,60].”
BackgroundResultInfluentialPCSK9 in metabolism and diseases
Ajoolabady, A., Pratico, D., Mazidi, M., Davies, I. G., Lip, G. Y. H., Seidah, N., Libby, P., Kroemer, G., & Ren, J. (2025) · Metabolism · doi:10.1016/j.metabol.2024.156064 · Cited by 49
Treatment of pancreatic cancer—neoadjuvant treatment in resectable pancreatic cancer (PDAC)
Seufferlein, T. T. W., & Ettrich, T. J. (2019) · Translational Gastroenterology and Hepatology · doi:10.21037/tgh.2019.03.05 · Cited by 49
Surgical treatment of metastatic pancreatic ductal adenocarcinoma: A review of current literature
Sakaguchi, T., Valente, R., Tanaka, K., Satoi, S., & Chiaro, M. D. (2019) · Pancreatology · doi:10.1016/j.pan.2019.05.466 · Cited by 49
Liu, Q., Zhang, R., Michalski, C. W., Liu, B., Liao, Q., & Kleeff, J. H. (2020) · Scientific Reports · doi:10.1038/s41598-020-61487-0 · Cited by 50
Güven, D. C., Şahin, T. K., Yildirim, H. Ç., Aktepe, O. H., Dızdar, Ö., & Yalçın, Ş. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103528 · Cited by 51
Pancreatic Ductal Adenocarcinoma: Molecular Pathology and Predictive Biomarkers
Taherian, M., Wang, H., & Wang, H. (2022) · Cells · doi:10.3390/cells11193068 · Cited by 67
“Currently, the main treatment options for patients with metastatic PDAC are gemcitabine/nab-paclitaxel, modified folinic acid, fluoracil, irinotecan, oxaliplatin (FOLFIRINOX), gemcitabine/capecitabine, irinotecan/fluorouracil, and single gemcitabine [80,81].”
BackgroundHuang, C., Zhou, W., Bian, A., Zhang, Q., Miao, Y., Yin, X., Ye, J., Xu, S., Ti, C., Sun, Z., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-0997 · Cited by 50
Roessler, M., Schmitt, J. M., Bobeth, C., Gerken, M., Tol, K. K.-V., Reißfelder, C., Rau, B., Distler, M., Piso, P., Günster, C., et al. (2022) · BMC Cancer · doi:10.1186/s12885-022-09731-w · Cited by 53
Sugawara, T., Franco, S. R., Sherman, S., Kirsch, M. J., Colborn, K. L., Ishida, J., Grandi, S., Al-Musawi, M. H., Gleisner, A., Schulick, R. D., et al. (2022) · JAMA Oncology · doi:10.1001/jamaoncol.2022.5808 · Cited by 48
Sadozai, H., Acharjee, A., Eppenberger‐Castori, S., Gloor, B., Gruber, T., Schenk, M., & Karamitopoulou, E. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.643529 · Cited by 55
Hosen, S. M. Z., Uddin, M. N., Xu, Z., Buckley, B. J., Perera, C. J., Pang, T., Mekapogu, A. R., Moni, M. A., Notta, F., Gallinger, S., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1060957 · Cited by 60
Targeting cancer-specific metabolic pathways for developing novel cancer therapeutics
Pal, S., Sharma, A. K., Mathew, S. P., & Jaganathan, B. G. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.955476 · Cited by 56
Botta, G. P., Abdelrahim, M., Drengler, R. L., Aushev, V. N., Esmail, A., Laliotis, G., Brewer, C. M., George, G. V., Abbate, S., Chandana, S. R., et al. (2024) · The Oncologist · doi:10.1093/oncolo/oyae155 · Cited by 60
Shaheen, N., Miao, J., Xia, B., Zhao, Y., & Zhao, J. (2025) · The FASEB Journal · doi:10.1096/fj.202500295r · Cited by 59
“Chemotherapy remains the primary treatment option for metastatic pancreatic ductal adenocarcinoma (PDAC), despite a response rate of less than 50% to initial therapies [83].”
Pentheroudakis, G. E. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz180 · Cited by 49
Anti-glypican-1 antibody–drug conjugate is a potential therapy against pancreatic cancer
Nishigaki, T., Takahashi, T., Serada, S., Fujimoto, M., Ohkawara, T., Hara, H., Sugase, T., Otsuru, T., Saito, Y., Tsujii, S., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0781-2 · Cited by 49
for the Dutch Pancreatic Cancer Group, Smits, F. J., Henry, A. C., van Eijck, C. H. J., Besselink, M. G., Busch, O. R., Arntz, M. J., Bollen, T. L., van Delden, O. M., van den Heuvel, D., et al. (2020) · Trials · doi:10.1186/s13063-020-4167-9 · Cited by 50
Surgical Treatment of Pancreatic Ductal Adenocarcinoma
Wei, K., & Hackert, T. (2021) · Cancers · doi:10.3390/cancers13081971 · Cited by 50
“The latest of these studies reported median survival times of 30 and 54 months, respectively, as well as a 5-year survival of 30% which shows the essential need for adjuvant systemic treatment after pancreatic cancer resection [26,28].”
BackgroundNeoadjuvant Treatment Strategies in Resectable Pancreatic Cancer
Lambert, A., Schwarz, L., Ducreux, M. P., & Conroy, T. (2021) · Cancers · doi:10.3390/cancers13184724 · Cited by 47
“However, the oral fluoropyrimidine S-1 is not available in Europe and the US.”
BackgroundInfluentialSelf-citationPerri, G., Prakash, L., Qiao, W., Varadhachary, G. R., Wolff, R. A., Fogelman, D. R., Overman, M. J., Pant, S., Javle, M. M., Koay, E. J., et al. (2019) · Annals of Surgery · doi:10.1097/sla.0000000000003763 · Cited by 46
Fiore, F. D., Bouché, O., Lepage, C., Sefrioui, D., Gangloff, A., Schwarz, L., Tuech, J., Aparicio, T., Lecomte, T., Boulagnon‐Rombi, C., et al. (2020) · Digestive and Liver Disease · doi:10.1016/j.dld.2020.03.031 · Cited by 49
Self-citationJin, J., Shi, Y., Chen, M., Qian, J., Qin, K., Wang, Z., Chen, W., Jin, W., Lu, F., Li, Z., et al. (2021) · Trials · doi:10.1186/s13063-021-05939-6 · Cited by 47
“The role of chemotherapy in PDAC has been long established, and different regimens have been identified to provide survival benefits [43, 44].”
BackgroundNarayanan, J. S. S., Hayashi, T., Erdem, S., McArdle, S., Tiriac, H., Ray, P., Pu, M., Mikulski, Z., Miller, A. M., Messer, K. S., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006133 · Cited by 51
“12 chemotherapy [37] There is intense interest in developing adjuvant immune strategies that can 332 eradicate micrometastatic disease.”
BackgroundTargeted therapy for pancreatic ductal adenocarcinoma: Mechanisms and clinical study
Kung, H., & Yu, J. (2023) · MedComm · doi:10.1002/mco2.216 · Cited by 46
Current Approaches for the Curative-Intent Surgical Treatment of Pancreatic Ductal Adenocarcinoma
Słodkowski, M., Wroński, M., Karkocha, D., Kraj, L., Śmigielska, K., & Jachnis, A. (2023) · Cancers · doi:10.3390/cancers15092584 · Cited by 56
“6 randomized phase III trial evaluated the effectiveness of a 6-month mFOLFIRINOX regimen compared with gemcitabine monotherapy [21].”
MethodA Simple Overview of Pancreatic Cancer Treatment for Clinical Oncologists
Garajová, I., Peroni, M., Gelsomino, F., & Leonardi, F. (2023) · Current Oncology · doi:10.3390/curroncol30110694 · Cited by 51
“…1 year; for locally advanced PDAC For metastatic PDAC patients, the OS outcome is less than 1 year; for locally advanced PDAC patients, the OS outcome is less than 2 years; for resectable PDAC patients who have undergone adjuvant FOLFIRINOX, an OS of 54 months has been reported [23,25,26,40,41,71].”
BackgroundInfluential
Metadata
- Authors
- Conroy, T., Hammel, P., Hebbar, M., Ben Abdelghani, M., Wei, A. C., Raoul, J.-L., Choné, L., Francois, E., Artru, P., Biagi, J. J., Lecomte, T., Assenat, E., Faroux, R., Ychou, M., Volet, J., Sauvanet, A., Breysacher, G., Di Fiore, F., Cripps, C., Kavan, P., Texereau, P., Bouhier-Leporrier, K., Khemissa-Akouz, F., Legoux, J.-L., Juzyna, B., Gourgou, S., O’Callaghan, C. J., Jouffroy-Zeller, C., Rat, P., Malka, D., Castan, F., & Bachet, J.-B.
- Affiliations
- Hôpital Beaujon (FR)
- From the Institut de Cancérologie de Lorraine and Université de Lorraine (T.C.) and Centre Hospitalier Universitaire (L.C.), Nancy, Hôpital Beaujon and University Paris VII, Clichy (P.H., A.S.), Hôpital Huriez, Lille (M.H.), Centre Paul Strauss, Strasbourg (M.B.A.), Institut Paoli-Calmettes, Marseille (J.-L.R.), Centre Antoine-Lacassagne, Nice (E.F.), Hôpital Jean-Mermoz, Lyon (P.A.), Hôpital Trousseau, Tours (T.L.), Centre Hospitalier Universitaire de Saint-Eloi (E.A.) and Institut du Cancer de...
- Université de Montpellier (FR)
- Université Paris-Saclay (FR)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-12-20
- Volume
- 379
- Issue
- 25
- Pages
- 2395-2406
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2903623792
- Cited by
- 2,874
- References
- 22
- Citations by year
- 2026: 219 · 2025: 316 · 2024: 337 · 2023: 457 · 2022: 449 · 2021: 512 · 2020: 376 · 2019: 202 · 2018: 1
- FWCI
- 102.29
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Funders
- Canadian Cancer Society (Program Grant #704970)
- Institut National du Cancer (Clinical Research Hospital Program grant (PHRC11-0)
- 7 Days in May
- French National League against Cancer
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
- Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
- Keywords
- FOLFIRINOX, gemcitabine, adjuvant chemotherapy, pancreatic ductal adenocarcinoma, resected pancreatic cancer, disease-free survival, overall survival, oxaliplatin, irinotecan, 5-fluorouracil, leucovorin, adverse events, treatment safety, secondary malignancies, metastatic pancreatic cancer, combination chemotherapy
- MeSH terms
- Irinotecan, Oxaliplatin, Gemcitabine, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Leucovorin, Deoxycytidine, Drug Combinations, Female, Fluorouracil, Humans, Male, Middle Aged, Organometallic Compounds, Pancreatic Neoplasms, Prospective Studies, Proportional Hazards Models, Chemotherapy, Adjuvant, Lung Diseases, Interstitial, Disease-Free Survival
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.